Recent Company News

• 06:10 AM ET Oct 18, 2025
  

  Merck, Eisai present long-term follow-up data on KEYTRUDA plus LENVIMA at ESMO

• 03:16 AM ET Oct 14, 2025
  

  BioArctic announces first patient treated with Leqembi (lecanemab) in the Nordics (SEK 291.00, -0.60)

• 06:51 AM ET Oct 09, 2025
  

  Merck announces new research to be presented at the ESMO Congress 2025 ($86.40, 0.00)

• 01:05 AM ET Oct 02, 2025
  

  Newron Pharmaceuticals to present new analyses and updates on its clinical program evaluating evenamide at ECNP Congress 2025 (CHF 10.92, 0.00)

• 07:38 PM ET Sep 28, 2025
  

  Biogen, Eisai advise approval in China for lecanemab IV maintenance dosing for the treatment of early alzheimer's disease ($137.37, 0.00)

• 12:50 PM ET Sep 26, 2025
  

  White House says the latest pharmaceutical tariffs do not apply to countries with negotiated trade deals -- wires

• 08:15 PM ET Sep 25, 2025
  

  Trump says pharmaceutical products imported into US will be hit with 100% tariff starting 1-Oct - Truth Social post

• 02:45 AM ET Sep 24, 2025
  

  BioArctic announces Australia approves lecanemab (Leqembi) for the treatment of early Alzheimer's disease (SEK 283.80, 0.00)

• 07:35 PM ET Sep 23, 2025
  

  Eisai enters into settlement agreement with Dr. Reddy's regarding Lenvatinib in the U.S (¥5180.0000, 0)

• 07:38 PM ET Sep 16, 2025
  

  Eisai receives FDA Fast Track Designation for Etalanetug (¥5183.0000, 0)